Retatrutide (development code LY3437943) is a 39-residue synthetic peptide that agonises three receptors at once — GIP, GLP-1 and glucagon — and the published phase-3 record in 2026 is still thinner than the headlines suggest. The peer-reviewed evidence base that anyone can read in full is dominated by phase-1 and phase-2 work; the phase-3 TRIUMPH programme has been reported largely through sponsor announcements and conference presentations, with primary papers arriving on a rolling basis. For anyone using retatrutide as a research reference standard, the distinction between published and announced is the whole story.
What retatrutide is, structurally
Retatrutide is built on a GIP-analog backbone rather than a GLP-1 backbone, which is the opposite design choice from tirzepatide's exendin-influenced scaffold. It carries a C20 fatty-diacid side chain for albumin binding, giving a reported half-life supportive of once-weekly administration in trials. The catalogue specification for research-grade lyophilised material lists CAS 2381089-83-2 and an average molecular weight of 4,731.30 Da — the number you need for any molarity calculation, not the vial label in milligrams. Our retatrutide research vials are supplied in 10 mg through 60 mg sizes, and the structural walkthrough lives in what is retatrutide.
The three-receptor design matters mechanistically. GLP-1 receptor agonism drives satiation and glucose-dependent insulin secretion; GIP receptor agonism appears to modulate adipose and central signalling; glucagon receptor agonism is the genuinely novel arm, implicated in hepatic lipid handling and energy expenditure rather than appetite alone. That third arm is why retatrutide is described as a triple agonist and why glucagon receptor pharmacology has become a live research question rather than a footnote.
What has actually been published
Reading the record in order helps separate evidence tiers.
| Stage | Population | Duration | Status of the record |
|---|---|---|---|
| Phase 1 (single/multiple ascending) | Healthy volunteers and type 2 diabetes | Up to 12 weeks | Fully published; established pharmacokinetics and the weekly interval |
| Phase 2 obesity | Adults with obesity, n ≈ 338 | 48 weeks | Fully published in a major journal in 2023; the most-cited retatrutide dataset |
| Phase 2 type 2 diabetes | Adults with T2D | 36 weeks | Fully published 2023 |
| Phase 2 substudies | Hepatic steatosis, knee osteoarthritis | 24–48 weeks | Reported as secondary and exploratory analyses |
| Phase 3 TRIUMPH programme | Obesity, T2D, OA, cardiovascular outcomes | Up to 3+ years | Topline sponsor announcements and congress presentations; full papers rolling out |
The 48-week phase-2 obesity trial is the number most articles are quoting even when they claim to be quoting phase 3. It reported mean body-weight reductions ranging from roughly 8–9% in the lowest milligram tier to approximately 24% in the highest tiers, against about 2% in the placebo arm, with a monotonic gradient across the milligram tiers. That gradient — clean, consistent, and larger at 48 weeks than incretin mono-agonists reported at similar timepoints — is what drove the attention. It is also a mid-size, 48-week trial: not an outcomes study, not powered for rare events, and not the same thing as a completed phase-3 filing package.
What the phase-3 programme is designed to answer
TRIUMPH splits the question. Separate arms address chronic weight management, type 2 diabetes with and without background therapy, obesity with knee osteoarthritis, and — critically — cardiovascular outcomes over multi-year follow-up. The outcomes arm is the one that will matter most for how retatrutide is ultimately positioned, because glucagon receptor agonism raises legitimate questions that a 48-week weight endpoint cannot settle: hepatic glucose output, resting heart rate, and whether increased energy expenditure is sustained or adapts.
When you read any 2026 summary of retatrutide, the useful test is simple. Ask which arm, what n, what duration, and whether the source is a peer-reviewed paper or a press release. Sponsor toplines report a primary endpoint and little else; the safety tables, discontinuation reasons, and subgroup behaviour only become assessable when the paper lands.
What has not been shown
No regulatory approval exists for retatrutide anywhere as of this writing, so every gram in circulation is investigational or research-grade. There is no published long-term cardiovascular outcome result, no head-to-head phase-3 against tirzepatide or semaglutide, and no human data at all for the specific lyophilised material sold for laboratory work — clinical data attach to the sponsor's characterised drug product, never to a research vial. Comparative framing against approved incretins is covered in retatrutide vs tirzepatide and semaglutide vs retatrutide.
Practical notes for laboratory use
Retatrutide is supplied as a lyophilised powder and is a strictly research-use-only material. Three handling points come up repeatedly. First, use 4,731.30 Da for molar calculations — a 10 mg vial is about 2.11 µmol, and reconstituted concentrations should be recorded in both mg/mL and molarity for reproducibility. Second, the acylated side chain makes the molecule surfactant-like at an air–liquid interface, so vigorous shaking during reconstitution is a real risk to peak shape on re-analysis; swirl instead. Third, the peptide is stable as a cake but not indefinitely stable in solution — see how to store peptides for the temperature and light guidance, and the reconstitution guide for the arithmetic.
Combination work is also active: pairing a triple agonist with an amylin analog is being explored in the literature, and a fixed-ratio retatrutide + cagrilintide research vial exists for that purpose. The wider incretin landscape, including the next wave of candidates, is mapped in the next GLP-1s compared, and the class-level overview sits in the weight-management research overview and the GLP-1 and incretin peptides collection.
The 2026 takeaway
Retatrutide is the most mechanistically ambitious incretin-family peptide with a substantial published dataset behind it, and the phase-2 magnitude is real and reproducible within its own programme. What it is not, yet, is a molecule with a complete, readable phase-3 safety and outcomes record. Treat the difference as a data-quality question rather than a marketing one, and cite the phase you are actually reading.